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Proliferation Arrest in B-Raf Mutant Melanoma Cell
Lines upon MAPK Pathway Activation
Roland Houben1, Sonja Ortmann1, Astrid Drasche2, Jakob Troppmair2, Marco J. Herold3 and
Ju¨rgen C. Becker1
Due to elaborate control mechanisms, in benign tumors the activation of oncogenes primarily induces
senescence, associated with cessation of cellular proliferation; for example, melanocytic nevi expressing mutant
B-Raf. These mechanisms include the RB and/or the p53 pathway. The current model of melanomagenesis
postulates that progression to immortal melanoma cells requires inactivating aberrations in signaling cascades
controlling senescence. Thus, melanoma cells carrying mutant B-Raf should be resistant to mitogen-activated
protein kinase (MAPK) pathway-induced senescence. Here, we demonstrate that hyperactivation of the MAPK
pathway following activation of an inducible form of oncogenic C-Raf induces a senescence-like proliferation
arrest in B-Raf mutant melanoma cells. This Raf-induced senescence is initially strictly dependent on MEK
signaling, but seems to be independent of MAPK signaling after prolonged continuance. It is associated with
reduced levels of RB phosphorylation and an increase in p21 expression, but is independent of p16Ink4a and p53.
These data argue against the existence of fundamental changes in melanoma cells completely precluding
senescence.
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INTRODUCTION
The mitogen-activated protein kinase (MAPK) pathway is a
major regulator of cell growth, differentiation, and survival. It
comprises the three consecutive kinases Raf, MEK (MAPK
kinase), and ERK (p42/p44 MAPK), which are controlled by
the small G-proteins of the Ras family (Zebisch and
Troppmair, 2006). Ras genes are the most frequently mutated
oncogenes in human tumors (Ellis and Clark, 2000). Their
downstream effector B-Raf, one of the three Raf isoforms, is
affected by activating mutations in several tumors with the
highest frequency present in melanoma (Davies et al., 2002).
The vast majority of B-Raf mutations leads to changes of the
valine in position 600 to a hydrophilic amino acid (most
frequently glutamic acid) probably mimicking the activating
phosphorylations at threonine 598 and serine 601. B-RafV600 0E
induces activation of MEK and ERK in cell culture
experiments and in vitro kinase assays (Houben et al.,
2004). This may in part be indirectly by B-Raf activating
C-Raf (Garnett et al., 2005). It is generally assumed that
transformation by activated B-Raf requires constitutive
activation of MAPK pathway (Rapp et al., 2006) for survival
and proliferation. In contrast, activation of MAPKs by
oncogenic Ras or Raf in primary cells leads to cell-cycle
arrest and a senescent phenotype (Michaloglou et al., 2005).
Normal mammalian cells (that is, non-stem, non-tumor
cells) have a finite proliferative potential in vitro after which
they irreversibly stop cycling. This process has been termed
replicative senescence and results from telomere shortening
during each cell division in the absence of telomerase
expression (Blagosklonny, 2006). In contrast to apoptosis,
replicative senescence represents a stable, long lasting state
in which cells remain viable and metabolically active for
extended periods of time (Chen, 2000). Such senescent cells
are characterized by an increased cell mass and frequently by
elevation of b-galactosidase activity (Blagosklonny, 2006).
Several lines of evidence suggest that replicative senescence
observed in vitro is related to organismal aging in vivo. In
contrast to differentiated cells, stem cells are characterized by
an active telomerase, which prevents telomere shortening
(Krtolica, 2005). Moreover, telomerase activation has been
suggested to contribute to cancer by avoiding telomere crisis
and thus replicative senescence (Chen, 2000; Stewart and
Weinberg, 2006).
The observation that senescence can be triggered inde-
pendently of telomere shortening by oncogenes has led to the
hypothesis that senescence may represent a safeguard
mechanism to prevent development of malignant tumors.
This security measure seems to respond directly to the
activation of certain oncogenes (Serrano et al., 1997) or loss
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of some tumor suppressors (Lin et al., 1998; Chen et al.,
2005). Indeed, recent work in both murine models and
humans supports this concept of oncogene-induced senes-
cence. For example, activating B-Raf mutations, which are
noted in approximately 50% of human melanoma, are also
present in the majority of nevi (Pollock et al., 2003), that is,
benign melanocytic tumors. demonstrated that sustained
expression of activated B-Raf in primary melanocytes
provoked b-galactosidase activity and growth arrest; accord-
ingly, B-RafV600E expressing nevi displayed strong b-galacto-
sidase staining and were negative for the proliferation marker
Ki67 in situ. The requirements for overcoming oncogene-
induced senescence have been explored in animal models. In
zebra fish, p53 loss cooperated with melanocyte-specific
B-RafV600E expression to turn BRafV600E-driven nevi formation
into melanoma development (Patton et al., 2005). Beside
p53, the p53 target p21, the p53 activator p19arf, as well as
the cyclin-dependent kinase (CDK) inhibitor p16INK4a have
been implicated in oncogene-induced senescence (Dankort
et al., 2007). Consequently, in the currently proposed models
of melanomagenesis inactivating events in these pathways
are regarded as prerequisite to allow B-Raf mutant melano-
cytes to evade senescence (Michaloglou et al., 2005; Braig
and Schmitt, 2006; Sarkisian et al., 2007). Hence, melanoma
cells should be resistant to oncogene-induced senescence.
Here we demonstrate that an enforced activation of the
MAPK pathway results in a senescent type proliferation arrest
of B-Raf mutant melanoma cell lines.
RESULTS
Hyperactivation of the MAPK pathway in B-Raf mutant
melanoma cell lines induces proliferation arrest
It has been proposed that mutant B-Raf drives the generation
of nevi. However, without additional interferences in path-
ways mediating oncogene-induced senescence melanoma-
genesis should not occur. (Michaloglou et al., 2005; Patton
et al., 2005; Gray-Schopfer et al., 2006; Mooi and Peeper,
2006). To test this hypothesis, we assessed whether B-Raf
mutant melanoma cells are indeed resistant to senescence
following an increase in MAPK activity. Fusion of the c-Raf-1
kinase domain (BXB) to a modified hormone binding domain
of the estrogen receptor results in a kinase (c-Raf-1-BXB-ER,
here referred to as Raf-ER) whose activity is dependent on the
presence of 4-hydroxytamoxifen (OHT) while retaining the
same target specificity as Raf (Kerkhoff and Rapp, 1997). The
melanoma cell line Skmel28 carrying a homo- or hemizygous
B-RafV600E mutation was infected with a virus carrying this
conditionally active Raf kinase (Skmel28 Raf-ER), a kinase
dead Raf-ER version (RafK375R-ER), or the empty EYZ vector
(SKmel28 EYZ). The unstimulated Skmel Raf-ER cells as well
as the controls displayed an equal basal level of ERK
phosphorylation in the absence as well as in the presence
of OHT, whereas the phospho-ERK signal was clearly
elevated on OHT stimulation of Skmel28 Raf-ER cells
(Figure 1a). Notably, these cells following OHT stimulation
stopped to proliferate (Figure 1b) but stayed viable (Figure 1c).
Moreover, Raf-ER cells largely reduced DNA synthesis on
OHT stimulation of Skmel28, indicated by decreases of BrdU
incorporation became evident (Figure 1d). Additional signs of
senescence were b-galactosidase expression, an increase in
cell size (Figure 1e) and a marked reduction in cells
expressing the proliferation marker ki-67 (Figure 1f). Titrating
the amount of OHT added to the culture medium of the
SKmel28 Raf-ER cells demonstrated that there was a close
correlation between the level of ERK activation and inhibition
of proliferation (Figure 2). Indeed, already a slight elevation of
ERK phosphorylation caused a measurable growth delay, and
a complete inhibition of proliferation was reached at
approximately half-maximal ERK phosphorylation. To con-
firm these unexpected observations two additional B-Raf
mutant melanoma cell lines, that is, Mel2a (B-RafV600E
heterozygous) and FM88 (B-RafV600K homo- or hemizygous)
were genetically engineered to express the OHT-sensitive Raf
fusion protein. Upon OHT stimulation both cell lines
exhibited elevated levels of ERK phosphorylation (Figure
3a), which were also associated with inhibition of prolifera-
tion in these two cell lines (Figures 3b and c). It should be
noted, however that the proliferation block was not
complete. Nevertheless, a reduction in ki-67 expressing cells,
reduced BrdU incorporation, as well as induction of
b-galactosidase were also evident in OHT stimulated Mel2a
Raf-ER and FM88 Raf-ER cells (data not shown).
MEK signaling is essential for the proliferation arrest induced by
Raf-ER activation
To confirm that the proliferation arrest induced by Raf
activation is indeed due to MAPK pathway signaling, we took
advantage of the specific MEK inhibitor U0126. Addition of
increasing amounts of inhibitor to cultures of SKmel28-Raf-
ER cells, simultaneously stimulated with OHT to activate
MAPK signaling, abolished the proliferation arrest. As a
matter of fact, a normal proliferation rate was reached at an
U0126 concentration, which decreased ERK activity to levels
seen in unstimulated cells (Figure 4). As expected, addition of
U0126 to Skmel28-Raf-ER cells growing in the absence of
OHT resulted in reduced proliferation (Figure 4). The same
effects were observed for FM88-Raf-ER and Mel2a-Raf-ER
cells (Figure 5, and data not shown). This observation
unequivocally demonstrates cells a narrow range of ERK
activity in B-Raf mutant melanoma, which is compatible with
a high proliferation rate. Both, elevation or reduction of the
MAPK signal still leads to impaired cell growth.
The MAPK pathway activation-induced proliferation arrest in
melanoma cells shifts from a reversible to an irreversible state
Replicative senescence is regarded to be irreversible (Chen,
2000). Oncogene-induced senescence, however, in some
experimental settings can be reversed; for example, activated
Ras may induce a growth arrest, which is reversible when Ras
activation is shut off (Sarkisian et al., 2007). To this end when
the OHT was removed following a 2-day incubation period,
no increase in proliferation compared to cells continuously
kept in the presence of OHT was observed (data not shown).
However, despite of extensive washing of the cells, the MAPK
signaling was not reduced to basal levels (data not shown)
suggesting an irreversible binding of OHT to the Raf-ER
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protein. Consequently, we used the MEK inhibitor U0126 to
reduce the MAPK signaling to basal levels. To this end, when
MEK signaling was blocked following a 2-day exposure of the
Skmel28- and Mel2a-Raf-ER cells to OHT, the manifest
replication block was overcome and the cells started to
proliferate again (Figure 5). It should be noted, however, that
when the preincubation with OHT was prolonged to 5 days,
addition of the MEK inhibitor did no longer lead to
reinduction of proliferation (Figure 5).
Reduced retinoblastoma protein (RB) phosphorylation upon
OHT stimulation of Raf-ER cells
The p16ink4a/RB and the p53/p21 pathways have been
implicated as prime mediators of oncogene-induced senes-
cence (Blagosklonny, 2006; Mooi and Peeper, 2006). The RB
protein is a critical regulator of the G1/S transition, that is, in
its hypophosphorylated state RB inhibits E2F-dependent
transcription of genes necessary for cell-cycle progression.
This block is reversed by phosphorylation of RB at multiple
sites through active cyclin/CDK complexes (Giacinti and
Giordano, 2006). In the present setting, RB phosphorylation
was reduced in the melanoma-Raf-ER cells upon OHT
stimulation as detected by western blot analysis using two
different antibodies specific for phosphoserine 807/811 or
phosphoserine 608, respectively (Figure 6). The RB phos-
phorylation was less reduced as for NIH3T3-Raf-ER cells; in
particular, Mel2a-Raf-ER cells displayed only a minor change
in serine 807/811 phosphorylation and no change in the
phosphoserine 608 signal. In contrast, for FM88-Raf-ER cells
there was a marked reduction of RB phosphorylation as
detected by both antibodies, whereas for Skmel28-Raf-ER
cells the change of the signal intensities upon Raf activation
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Figure 1. Induction of ERK phosphorylation and a senescence type proliferation arrest by 4-hydroxytamoxifen (OHT) stimulation of Skmel28-Raf-ER cells.
SKmel28 Raf-ER cells expressing c-Raf-1-BXB-ER, SKmel28 Raf-ERK375R expressing a kinase dead RAF-ER protein, and Skmel28 EYZ cells stably transfected with
the empty vector were incubated in the presence of 200 nM OHT. As control, the adequate amount of the solvent (EtOH) was added to the medium. (a) Twenty-
four hours following OHT stimulation, total cell lysates were subjected to western blot analysis and probed with the indicated antibodies. For western blot
analysis, 2 105 cells per well were seeded in 6-well plates. (b) At the indicated time points following OHT stimulation, detached and adherent cells were
pooled, pelleted, and resuspended in trypan blue solution. The number of cells excluding trypan was plotted against time. (c) The percentage of cells, not
excluding trypan blue, was plotted against time. For assessment of proliferation and viability 4 103 cells per well were seeded in duplicates in 48-well plates.
(d) Skmel28 Raf-ER cells were seeded with 0.5104 cells per well in triplicates in 96-well plates. Following 20 hours in the absence or presence of OHT, cells
were incubated for 3 hours with BrdU. BrdU incorporation was than measured by an immunoassay. (e) After 6 days in the presence or absence of OHT, Skmel28
Raf-ER cells were trypsinized and subjected to an X-Gal assay to visualize expression of b-galactosidase. (f) Following 2 days in the absence or presence of OHT
Skmel28 Raf-ER cells were analyzed by flow cytometry for the expression of ki-67.
408 Journal of Investigative Dermatology (2009), Volume 129
R Houben et al.
MAPK Pathway Activation on B-Raf Mutant
was in between those observed for the two other melanoma
cell lines. However, in case of these cells, which show the
most definite proliferation arrest, a shift toward a lower
molecular weight was obvious for phosphoserine 807/811.
This observation may be due to the presence of RB protein
still phosphorylated at serine 807/811, but dephosphorylated
at other sites resulting in a faster mobility in gel electrophor-
esis. The reduction in RB phosphorylation in the melanoma-
Raf-ER cells, however, was not associated with an increase in
expression of p16ink4a, an inhibitor of cyclinD/CDK4/6. The
p16ink4a expression was unaltered upon OHT stimulation,
that is, high in Skmel28- and Mel2a-Raf-ER cells and not
detectable in FM88-Raf-ER cells (Figure 6). In contrast, the
CDK inhibitor p21 which inhibits preferentially CyclinE/
CDK2 is clearly induced by Raf activation in Skmel28- and
Mel2a-Raf-ER cells as well as, albeit to a lesser extent, in
FM88- and NIH3T3-Raf-ER cells (Figure 6). Expression levels
of the p21 regulator p53, however, remained unchanged and
it is therefore unlikely that p53 is involved in upregulation of
p21 induced by OHT.
Lack of G1 cell-cycle arrest upon MAPK pathway activation in
melanoma-Raf-ER cells
Most authors emphasize the role of RB phosphorylation for
the G1/S transition (Giacinti and Giordano, 2006). Therefore,
we analyzed the distribution of cells throughout the cell cycle
upon MAPK-induced proliferation arrest. This was achieved
by measuring the cellular DNA content by means of flow
cytometry. On MEK inhibition, all Raf-ER cell lines accumu-
late in G1 (Figure 7). In contrast, the proliferation arrest upon
MAPK pathway activation in Skmel28-Raf-ER and Mel2a-Raf-
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Figure 2. Correlation of ERK phosphorylation and proliferation upon
titration of 4-hydroxytamoxifen (OHT) to Skmel28-Raf-ER cells. Skmel28-
Raf-ER cells were incubated with the indicated concentration of OHT and
24hours following OHT stimulation total cell lysates were subjected to
western blot analysis and probed with the indicated antibodies. Proliferation
of the cells was assessed using the MTS assay after 5 days of incubation with
OHT. For the MTS assay, the cells were seeded in triplicates with 1 103 cells
per well in 96-well plates.
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Figure 3. Induction of ERK phosphorylation and proliferation arrest by 4-hydroxytamoxifen (OHT) stimulation of Mel2a-Raf-ER, FM88-Raf-ER, and
NIH3T3-Raf-ER cells. The melanoma cell-line derivates, Mel2a-Raf-ER and FM88-Raf-ER as well as NIH3T3-Raf-ER, expressing c-Raf-1-BXB-ER were incubated
in the presence of 200 nM OHT. To unstimulated cells adequate amount of the solvent (EtOH) was added to the medium. (a) At the indicated time points
following OHT stimulation total cell lysates were subjected to western blot analysis and probed with the indicated antibodies. For western blot analysis 2 105
cells per well were seeded in six-well plates. (b–d) At the indicated time points following OHT stimulation, detached and adherent cells were pooled, pelleted,
and resuspended in trypan blue solution. The number of cells excluding trypan was plotted against time. For assessment of proliferation and viability 1 104
cells per well were seeded in duplicates in 24-well plates.
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ER cells is not associated with significant changes in cell-
cycle distribution, particularly a G1 accumulation (Figure 7).
For the FM88-Raf-ER cells 24 hours following OHT stimula-
tion, the cell-cycle distribution is unchanged, whereas at the
same time point the U0126-treated cells display an increased
percentage of cells with 2N DNA content. For later time
points the cell-cycle distribution of FM88-Raf-ER cells treated
with the MEK inhibitor could not be quantified, due to the
onset of massive apoptotic cell death. The OHT-treated
FM88-Raf-ER cells at 48 and 62 hours were the only
melanoma cells, which displayed at best a slight accumula-
tion in G1 upon MAPK pathway activation. In contrast, the
NIH3T3-Raf-ER cells clearly arrested in G1 and G2 upon OHT
treatment (Figure 7) as described before (Kerkhoff and Rapp,
1998). Taken together our data indicate that the proliferation
arrest induced by MAPK pathway activation in B-Raf mutant
melanoma cells is not restricted to a distinct cell-cycle phase.
Signaling crosstalk upon Raf-ER activation
A multifaceted crosstalk between signaling pathways, espe-
cially between the MAPK pathway and the AKT or the NF-kB
pathway, has been reported (Troppmair et al., 1998;
Baumann et al., 2000; Moelling et al., 2002; Myhre et al.,
2004; Sato et al., 2004; Hsiung et al., 2005; Liu et al., 2006).
For example, prolonged activation of Raf resulted in the
concomitant activation of PI3K/AKT in myeloid and epithelial
cells (Schulze et al., 2001; von Gise et al., 2001). To detect a
possible dependency of AKT or NF-kB signaling on the MAPK
pathway we analyzed AKT and IkB kinase-a (IKK-a)
phosphorylation in SKmel28-Raf-ER cells treated with OHT
and/or U0126. Similarly to the effects described for other
cells, we found a positive correlation with MAPK activity for
both pathways. Phospho-AKT levels as well as phospho-IKK-
a levels were reduced upon U0126 treatment and increased
upon OHT stimulation (Figure 4b). Furthermore, through the
addition of U0126 elevation of AKT and IKK-a phosphoryla-
tion in OHT-treated cells could be blocked, demonstrating
that these effects are mediated via the MAPK pathway and not
via alternative Raf targets (Figure 4b).
DISCUSSION
Melanoma is the tumor entity which harbors the highest
frequency of B-Raf mutations (Davies et al., 2002) and this
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mutational state in situ is well preserved by in vitro expansion
(Ugurel et al., 2007). Moreover, B-Raf mutant melanomas
depend on Raf-driven activation of the MAPK pathway for
maintenance and progression (Rapp et al., 2006). Therefore,
melanoma is of particular interest in the evaluation of Raf and
MEK kinase inhibitors, which are currently in clinical trials for
the treatment of several cancers (Becker et al., 2006). Here,
we demonstrate that in B-Raf mutant melanoma cell lines
already possessing constitutive MAPK activation further
increasing MAPK activity (in our experimental setting by
means of a hormone-regulated Raf-ER protein) leads to a
senescence-like proliferation arrest. Cellular senescence is
considered as a safeguard mechanism that prevents aged or
potentially oncogenic cells from further expansion (Braig and
Schmitt, 2006). Manifest oncogene-induced senescence can
be reverted by experimental suppression of p53 (Dirac and
Bernards, 2003) or RB function (Sage et al., 2003). However,
it remains an open question whether malignant tumors
emerge from a senescent cell upon acquisition of an escape
mutation or expand from a clone that bypassed senescence
(Braig and Schmitt, 2006). Notably, malignant melanoma in
10–30% of cases appears to be associated with a nevus (Stolz
et al., 1989; Carli et al., 1999). The data presented here
indicate that B-Raf mutant melanoma cells do not completely
evade the mechanisms of senescence, but rather have
adopted to proliferate with an optimal replication rate at
somewhat higher levels of MAPK pathway activity. Indeed,
all B-Raf mutant melanoma cell lines analyzed here are very
sensitive to both inhibition as well as elevation of MAPK
pathway activity.
p16 expression frequently serves as a marker for senescent
cells (Chen, 2000). The coincidence of senescence and p16
expression in nevi and the frequently observed absence of
p16 in melanoma suggests a role of this CDK inhibitor
preventing immortalization of melanocytes. However, in
primary melanocytes activated Raf-induced p16 expression
but the ablation of p16 did not affect B-RafV600E-induced
senescence (Michaloglou et al., 2005). Moreover, nevi from
p16 deficient patients grow larger, but still undergo growth
arrest at some point (Gruis et al., 1998; Tucker et al., 2002).
The growth arrest induced by Raf-ER activation in the three
melanoma cell lines was not associated with induction of
p16; thus excluding an involvement of this CDK inhibitor.
Recently, a revised model for oncogene-induced senes-
cence was proposed, which is based on the observation that
aberrant Ras/Raf signaling induces a negative feedback loop
attenuating MAPK and AKT signaling; especially reduction of
signaling in the AKT pathway is required for senescence
(Courtois-Cox et al., 2006). In one of their experiments
Courtois-Cox et al. demonstrated that AKT phosphorylation
was downregulated upon Raf-ER activation in human
fibroblasts. This is in complete difference to the effect of
MAPK hyperactivation in transformed melanoma cells, that
is, Raf-ER activation provoked an increased AKT activation.
The proliferation arrest upon OHT stimulation in melano-
ma-Raf-ER cell lines is not associated with a G1 or a G2 cell-
cycle arrest as it is the case upon MEK inhibition of the
melanoma cells or in OHT-treated NIH3T3-Raf-ER cells. This
is an unexpected observation because in several other cell
systems MAPK pathway hyperactivation results in a G1 arrest
(Serrano et al., 1997; Olsen et al., 2002; Spyridopoulos et al.,
2002). This might be an indication of a differing mechanism
leading to growth arrest. On the other hand MAPK pathway
activation in the B-Raf mutant melanoma cells leads to p21
induction and/or RB dephosphorylation as described before
for fibroblasts and other systems (Courtois-Cox et al., 2006);
in contrast, p53, which is an transcriptional inducer of p21
and has been described as mediator of oncogene-induced
senescence (Serrano et al., 1997), seems not to be involved.
RB phosphorylation is required for the G1/S transition
(Giacinti and Giordano, 2006), but it is also necessary for
progression through the S phase of the cell cycle (Knudsen
et al., 1998). Similarly, p21 has been implicated in G1-phase
arrest as well as in S-phase arrest (Zhu et al., 2004).
Therefore, p21 induction and hypophosphorylated RB may
be critical for the observed proliferation arrest without
accumulation in G1.
Here, we have demonstrated that even in melanoma cells
carrying activating B-Raf mutations, further elevation of
MAPK signaling leads to a senescence type proliferation
arrest. Given the heterogeneity of the tumor cells in situ, and
as oncogene-induced senescence has been demonstrated
recently to occur in melanocyte derived cells in vivo
(Michaloglou et al., 2005), it is conceivable that in
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signals in the murine NIH3T3 Raf-ER cells were only detectable upon
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melanomas a sub-population of cells with elevated levels of
MAPK pathway activity reside in a growth-arrested state.
MAPK pathway inhibitors currently tested for the treatment of
melanoma might therefore inhibit growth of tumor cells with
median MAPK pathway activity while promoting prolifera-
tion of melanoma cells with high MAPK pathway activity.
Such a scenario interfering with the effectiveness of such
drugs is supported by the demonstration that Ras-induced
senescence in an animal model can be reversed by shutting
down Ras activity (Sarkisian et al., 2007). Consequently,
agents which are specifically toxic to B-Raf mutant cells
without affecting the MAPK pathway may be an attractive
alternative (Yagoda et al., 2007).
MATERIALS AND METHODS
Retroviral transduction
The bicistronic retroviral vector pEYZ has been published previously
(Kuss et al., 1999) and cloning of the pEYZ-c-Raf-1-BXB-ER vector
(Raf-ER) has been described (Houben et al., 2007). Retroviruses were
raised in HEK293T cells transfected with pHIT60 and pVSVg helper
constructs in addition to either pEYZ empty vector or pEYZ-c-Raf-1-
BXB-ER. Two days following transfection, virus supernatants were
harvested and filtered through 0.45 mm pore-size filters. SKmel28,
Mel2a, and FM88 were incubated for 3 days in the presence of virus
supernatants, and stably transduced cells were selected in medium
containing Zeocin (100 mg/ml). Generation of the cell line, NIH3T3-
Raf-ER has been described elsewhere (Kerkhoff and Rapp, 1998).
Cell culture
The melanoma cell lines, SKmel28, Mel2a, and FM88 and their
descendents as well as the NIH3T3 fibroblasts were grown in RPMI
1640 supplemented with 10% fetal bovine serum, 100U/ml
penicillin and 0.1mg/ml streptomycin. To determine the B-Raf
status of the cells, genomic DNA was isolated and B-Raf-specific
PCR was performed followed by sequencing of the PCR products as
described (Houben et al., 2004). SKmel28 cells were found to be
homo- or hemizygous for B-RafV600E, Mel2a cells were heterozygous
for B-RafV600E, and the FM88 cells were homo- or hemizygous for B-
RafV600K. As activator of the Raf-ER protein OHT (Sigma, Ottobrunn,
Germany), as MEK inhibitor U0126, the AKT inhibitor VII, and as
NF-kB inhibitor SN50 (all Calbiochem, Frankfurt, Germany) were
added to the culture medium; the stock solutions were 200 mM in
EtOH, 10mM in DMSO, 2mM in phosphate-buffered saline (PBS),
and 0.5mM in PBS, respectively. The corresponding amount of the
appropriate solvent was added to the culture medium of the control
cells. The study analyzing exclusively established cell lines was
conducted according to Declaration of Helsinki Principles.
Trypan blue and MTS assay
To determine the cell number and viability of the cells, detached and
adherent cells were pooled, pelleted, and resuspended in trypan
blue solution. Subsequently, the number of cells excluding or not
excluding trypan blue were counted using a Neubauer chamber.
Alternatively, proliferation and cell viability was assessed by the
MTS assay (CellTiter 96 AQueous One Solution Cell Proliferation
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Figure 7. Cell-cycle distribution following activation or inactivation of the mitogen-activated protein kinase (MAPK) pathway. Cells were seeded with
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assay; Promega Corporation, Madison, WI). Cells were seeded in 96-
well plates and incubated for 3–5 days. At the end of incubation, 20ml
of CellTiter 96 AQueous One Solution Reagent containing a
tetrazolium compound (MTS) were added to each well and the cells
were incubated for approximately 60min at 371C. Metabolically active,
viable cells convert MTS into a colored formazan product that was
measured in a spectrophotometric microplate reader (Perkin-Elmer Inc.,
Wiesbaden, Germany) at 493nm. The differences measured between
uninduced cells and OHT-stimulated cells were generally less
significant using the MTS assay than by counting the cells. This may
be due to the enlarged volume of the OHT-treated cells (Figure 1e).
BrdU incorporation and X-Gal assay
Cells were seeded with 0.5 104 cells per well in triplicates in
96-well plates. Following 20hours in the absence or presence of
OHT, a BrdU incorporation kit (Calbiochem) was applied according
to the instructions of the manufacturer, with a BrdU incubation
period of 3 hours. Quantification was done in a spectrophotometric
microplate reader (Perkin-Elmer Inc.) at 450 nm.
A senescence detection kit (Biovision, Mountain View, CA),
which is an X-Gal assay for the visualization (blue color) of
senescence associated b-galactosidase activity, was applied accord-
ing to the instructions of the manufacturer.
Western blot
For protein analysis, cells cultured under the indicated conditions
were lysed on ice using Laemmli buffer (130mM Tris/HCl pH 6.8, 4%
SDS, 20% glycerol, 20mg/ml bromphenol blue, 4% 2-mercaptoethanol).
Cell lysates were resolved by SDS–PAGE and transferred to
nitrocellulose membranes. Following blocking for 1 hour with PBS
containing 0.05% Tween 20 and 5% powdered skim milk, blots were
incubated for 2hours or overnight with primary antibody, washed
three times with PBS supplemented with 0.05% Tween 20, and then
incubated with the appropriate peroxidase-coupled secondary anti-
body (DAKO Cytomation, Hamburg, Germany). Following extensive
washing the bands were detected using a chemo luminescence
detection kit (Roche Diagnostics, Mannheim, Germany). The primary
antibodies (clone; dilution or concentration) were a-Phospho-p44/42
MAPK (Thr202/Tyr204) (clone E10; 1/2000), a-phospho RB (Ser807/
811) (rabbit polyclonal; 1/1000), a-phospho RB (Ser609) (rabbit
polyclonal; 1/1000), a-AKT (rabbit polyclonal; 1/1000), a-phospho-
AKT (S473) (rabbit polyclonal; ), a-IKKa (rabbit polyclonal; 1/500),
a-phospho-IKKa (S180) (rabbit polyclonal; 1/1000) (all Cell Signaling,
Beverly, MA), a-b-tubulin (TUB2.1; 1/2500) (Sigma), a-p16ink4a
(LabVision, Fremont, CA), a-p21 (C19; 1mg/ml), and a-p53 (DO-1;
1mg/ml) (both Santa Cruz, Santa Cruz, CA).
Flow cytometry
For detection of cellular DNA content cells in the supernatant as well
as the cells that still attached to the culture plate were harvested and
resuspended in 0.5ml PBS supplemented with 1% fetal calf serum.
Ice-cold EtOH (5ml) was added followed by an overnight incubation
at 41C. The fixed cells were pelleted and resuspended in 1ml PBS
supplemented with 1% fetal calf serum, 0.05mg/ml propidium
iodide, and 0.1mg/ml RNase A. Following a 1 hour incubation at
371C, analysis of the cellular DNA content was performed on a
FACSCanto flow cytometer (Becton & Dickinson, Heidelberg,
Germany), and the Cylchred software was used to evaluate data.
For the analysis of ki-67 expression, cells were trypsinized,
followed by two washes with PBS. Than they were fixed with ice-
cold 80% ethanol for 2 hours. Following two washes in staining
solution (PBS supplemented with 1% fetal calf serum), cells were
incubated with anti-Ki-67 antibody (clone B56; 1/25 diluted)
(BD Biosciences, San Jose, CA) for 30minutes, washed twice,
incubated with the FITC-labeled secondary antibody, washed again
twice, and finally fluorescence was measured on a FACSCanto flow
cytometer.
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